Abemaciclib is an oral cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor, approved by the US FDA for treating HR+/HER2- advanced breast cancer . CDK 4/6 inhibitors are the preferred treatment option for HR+/HER2- advanced breast cancer. The EML expert committee recognised its potential for future inclusion and recommended that MPP explore licensing opportunities to support affordable access. Abemaciclib primary patents have been granted in more than 40 LMICs and are expected to expire in 2029 in most countries.

Patent & licence data in LMICs

Acronyms & abbreviations list